Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
NCT03496766 · Spanish Lung Cancer Group · PHASE2 · terminated · last registry update 2025-03-05 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The recruitment was closed prematurely to due to slow recruitment.” | Open Targets' class: insufficient enrollment | Registry record, Spanish Lung Cancer Group |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FNTA in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision